<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693784</url>
  </required_header>
  <id_info>
    <org_study_id>SR-BX01P-2007</org_study_id>
    <nct_id>NCT00693784</nct_id>
  </id_info>
  <brief_title>Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System: A Pilot Study</brief_title>
  <official_title>A Multicenter Pilot Study of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spinal Restoration, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spinal Restoration, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety of the Biostat Disc Augmentation System for
      the treatment of chronic low-back (lumbar) pain due to symptomatic internal disc disruptions
      (IDD) and to obtain preliminary efficacy information.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Biostat Disc Augmentation System is a combination product combining a resorbable biologic
      product with a delivery device system used to prepare and insert the biologic material into a
      lumbar intervertebral disc.

      Symptomatic IDD is defined as a painful disruption of the internal architecture of a lumbar
      intervertebral disc, which appears as fissures, cracks or tears within the internal
      structures of the disc. Pain arising from a lumbar disc may not only be perceived as pain
      located in the low back (axial pain), but also as somatic referred pain involving the
      posterior hips, buttock, lateral hips, groin, or posterior thighs.

      The diagnosis of symptomatic IDD cannot currently be made on the basis of imaging studies,
      physical examination, or symptoms alone, and must be established with meticulously conducted
      disc provocation studies (provocation discography) that include pressure manometry, and
      identification of an adjacent normal disc.

      This treatment and study are not designed for patients exhibiting other potential sources of
      chronic low back pain such as more advanced degenerative disc disease with significant loss
      of disc height (&gt; 33%), spinal stenosis, or spondylolisthesis (see Eligibility Criteria).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers and Types of Adverse Events (Only Number of Events is Reported in This Section - See Adverse Events Section for Further Detail)</measure>
    <time_frame>104 weeks</time_frame>
    <description>The primary outcome for this safety study includes the number and types of adverse events reported in the study. The data fields in this section do not allow for reporting all aspects of this outcome (i.e., the number of adverse events, as well as the types of event). These numbers were entered and are reported in the adverse event section of the Results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale for Low-back Pain</measure>
    <time_frame>Baseline, 26-weeks (primary endpoint), 52-weeks, 104-weeks</time_frame>
    <description>100 mm line anchored on the left with the descriptor &quot;No pain&quot; (best value = 0 mm) and anchored on the right with the descriptor &quot;Worst possible pain&quot; (worst value = 100 mm). Lower scores indicate less pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Roland-Morris Disability Questionnaire</measure>
    <time_frame>Baseline, 26-weeks (primary endpoint), 52-weeks, 104-weeks</time_frame>
    <description>24-item questionnaire with score determined by the number of items checked by the subject. Items assess the effect of back pain on limitations of normal daily activities. Best value = 0 (least disability). Worst value = 24 (most disability). Higher number indicate greater disability.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Biostat® Disc Augmentation System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biostat® Disc Augmentation System</intervention_name>
    <description>Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device</description>
    <arm_group_label>Biostat® Disc Augmentation System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 (inclusive) and skeletally mature.

          -  Voluntarily signs the subject informed consent form and agrees to the release of
             medical information for purposes of this study (HIPAA authorization).

          -  Physically and mentally able to comply with the protocol, including ability to read
             and complete required forms, and willing and able to adhere to the follow-up
             requirements of the protocol.

          -  Low-back pain for at least 6 months.

          -  Pretreatment baseline low-back pain of at least 40 mm on a 100 mm visual analog scale.

          -  Referred leg pain, if present, is of noncompressive origin and there are no clinical
             findings of radiculopathy.

          -  Low-back pain is greater than leg pain (if present) as measured on a visual analog
             scale. If bilateral leg pain, back pain is greater than worst leg pain.

          -  Low-back pain unresponsive to at least 6 weeks of nonoperative treatment, which may
             include bed rest, antiinflammatory and analgesic medications, chiropractic
             manipulations, acupuncture, massage, physical therapy or home-directed lumbar exercise
             program.

          -  Negative response to diagnostic medial branch block or facet joint injection.

          -  No sustained relief with epidural injection of corticosteroids.

          -  Diagnosis of symptomatic lumbar (L1/L2-L5/S1) internal disc disruption (IDD), which
             requires confirmation of discogenic pain at one or two contiguous levels through
             positive provocation discography performed using pressure manometry and identification
             of an adjacent normal disc. The disc provocation studies must precisely demonstrate
             concordant pain (&lt;50 psi above opening pressure) and must demonstrate a fissure(s) in
             the outer one-third of the posterior or lateral anulus.

        Exclusion Criteria:

          -  Cauda equina syndrome.

          -  Active malignancy or tumor as source of symptoms.

          -  Infection at the planned procedure site or active systemic infection.

          -  Previous lumbar spine surgery.

          -  Previous disc invasive treatment procedures at the affected level(s) (e.g.,
             intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation) in
             the past 12 months or intradiscal corticosteroid injection within the past 3 months.

          -  Evidence of prior lumbar vertebral body fracture or trauma.

          -  Disc bulge/protrusion at the symptomatic level(s) &gt; 4 mm.

          -  Presence of disc extrusion or sequestration.

          -  Clinical findings of lumbosacral motor or sensory radiculopathy.

          -  Leg pain is greater than low-back pain as measured on a visual analog scale.

          -  Lumbar intervertebral foramen stenosis at the affected level(s) resulting in
             significant spinal nerve root compression or impingement.

          -  Symptomatic central vertebral canal stenosis or absolute sagittal vertebral canal
             diameter &lt; 9mm.

          -  Loss of disc space height at the symptomatic level(s) greater than one-third of an
             adjacent normal disc (or of the expected height in the case of an L5-S1 disc).

          -  Spondylolisthesis (≥ Grade 1) with or without spondylolysis at the symptomatic
             level(s).

          -  Lumbar spondylitis or other undifferentiated spondyloarthropathy.

          -  Dynamic instability on lumbar flexion-extension radiographs.

          -  Positive response to diagnostic medial branch block or facet joint injection.

          -  Positive response to diagnostic sacroiliac joint injection for those patients with
             pain in the sacral region

          -  Sustained relief obtained with epidural injection of corticosteroids.

          -  Symptomatic involvement of more than two lumbar disc levels.

          -  Congenital or acquired coagulopathy or thrombocytopenia; or currently taking
             anticoagulant, antineoplastic, antiplatelet, or thrombocytopenia-inducing medications.

          -  History of unexplained, easy, or persistent bruising or bleeding, bleeding from the
             gums, or bleeding problems experienced in previous surgical procedures.

          -  Aspirin or aspirin-containing medication taken ≤7 days prior to the procedure.

          -  Significant systemic disease, including unstable angina, autoimmune disease,
             rheumatoid arthritis, and muscular dystrophy.

          -  Known or suspected hypersensitivity or allergy to drugs or components of the fibrin
             sealant, including aprotinin, used in the procedure.

          -  History of, or current psychiatric condition, substance or alcohol abuse that would
             potentially interfere with the subject's participation in the study.

          -  Ongoing or previous participation in another drug or device clinical study within the
             previous 2 months.

          -  Subject known to be pregnant or nursing at time of enrollment or with plans to become
             pregnant within the planned length of follow-up (2 years).

          -  Body habitus precludes adequate fluoroscopic visualization for the procedure or the
             procedure is physically impossible using the device.

          -  Concomitant conditions requiring daily oral steroid usage for more than 30 days in the
             preceding 90 days.

          -  Pending litigation against a health care professional, except where required by the
             insurer as a condition of coverage.

          -  Prisoner or active military personnel who would not be available for follow-up.

          -  Presence of ferromagnetic implants that would disallow MRI of the symptomatic disc(s).

          -  Active or pending workers' compensation claims.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin J Pauza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spine Specialists, PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <results_first_submitted>March 8, 2010</results_first_submitted>
  <results_first_submitted_qc>April 7, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2010</results_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intervertebral Disk</keyword>
  <keyword>chronic low back pain</keyword>
  <keyword>internal disc disruption</keyword>
  <keyword>degenerative disc disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIOSTAT BIOLOGX</title>
          <description>1 injection of from 1 to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>26-Week Primary Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>52-week Extended Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>104-week Extended Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIOSTAT BIOLOGX</title>
          <description>1 injection of from 1 to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numbers and Types of Adverse Events (Only Number of Events is Reported in This Section - See Adverse Events Section for Further Detail)</title>
        <description>The primary outcome for this safety study includes the number and types of adverse events reported in the study. The data fields in this section do not allow for reporting all aspects of this outcome (i.e., the number of adverse events, as well as the types of event). These numbers were entered and are reported in the adverse event section of the Results.</description>
        <time_frame>104 weeks</time_frame>
        <population>All 15 participants available through 26-week primary endpoint. One voluntary withdrawal and 1 lost-to-follow-up between 26-week follow-up and 52-week extended follow-up. One additional voluntary withdrawal and 1 additional lost-to-follow-up between 52-week extended follow-up and 104-week extended follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>BIOSTAT BIOLOGX</title>
            <description>1 injection of from 1 to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers and Types of Adverse Events (Only Number of Events is Reported in This Section - See Adverse Events Section for Further Detail)</title>
          <description>The primary outcome for this safety study includes the number and types of adverse events reported in the study. The data fields in this section do not allow for reporting all aspects of this outcome (i.e., the number of adverse events, as well as the types of event). These numbers were entered and are reported in the adverse event section of the Results.</description>
          <population>All 15 participants available through 26-week primary endpoint. One voluntary withdrawal and 1 lost-to-follow-up between 26-week follow-up and 52-week extended follow-up. One additional voluntary withdrawal and 1 additional lost-to-follow-up between 52-week extended follow-up and 104-week extended follow-up.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale for Low-back Pain</title>
        <description>100 mm line anchored on the left with the descriptor &quot;No pain&quot; (best value = 0 mm) and anchored on the right with the descriptor &quot;Worst possible pain&quot; (worst value = 100 mm). Lower scores indicate less pain.</description>
        <time_frame>Baseline, 26-weeks (primary endpoint), 52-weeks, 104-weeks</time_frame>
        <population>n=15 (all participants at baseline and 26-week primary endpoint) n=13 at 52 weeks n=11 at 104 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>BIOSTAT BIOLOGX</title>
            <description>1 injection of from 1 to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale for Low-back Pain</title>
          <description>100 mm line anchored on the left with the descriptor &quot;No pain&quot; (best value = 0 mm) and anchored on the right with the descriptor &quot;Worst possible pain&quot; (worst value = 100 mm). Lower scores indicate less pain.</description>
          <population>n=15 (all participants at baseline and 26-week primary endpoint) n=13 at 52 weeks n=11 at 104 weeks</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26-wks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52-wks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104-wks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Roland-Morris Disability Questionnaire</title>
        <description>24-item questionnaire with score determined by the number of items checked by the subject. Items assess the effect of back pain on limitations of normal daily activities. Best value = 0 (least disability). Worst value = 24 (most disability). Higher number indicate greater disability.</description>
        <time_frame>Baseline, 26-weeks (primary endpoint), 52-weeks, 104-weeks</time_frame>
        <population>n=15 (all participants at baseline and 26-week primary endpoint) n=13 at 52 weeks n=11 at 104 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>BIOSTAT BIOLOGX</title>
            <description>1 injection of from 1 to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant</description>
          </group>
        </group_list>
        <measure>
          <title>Roland-Morris Disability Questionnaire</title>
          <description>24-item questionnaire with score determined by the number of items checked by the subject. Items assess the effect of back pain on limitations of normal daily activities. Best value = 0 (least disability). Worst value = 24 (most disability). Higher number indicate greater disability.</description>
          <population>n=15 (all participants at baseline and 26-week primary endpoint) n=13 at 52 weeks n=11 at 104 weeks</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>26-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>52-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>104-weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>104 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BIOSTAT BIOLOGX</title>
          <description>1 injection of from 1 to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>custom</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Discitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Tumor</sub_title>
                <description>Kidney tumor present but undetected at baseline.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>custom</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Trip/fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Motor vehicle accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Buttock Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Low back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeff F. Doerzbacher</name_or_title>
      <organization>Spinal Restoration, Inc.</organization>
      <phone>512 225-0405</phone>
      <email>jeffdoerzbacher@spinalrestoration.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

